# **Announcement Summary**

# **Entity name**

CRESO PHARMA LIMITED

## **Announcement Type**

New announcement

## Date of this announcement

19/5/2023

# The Proposed issue is:

# Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
CPHOD	OPTION EXPIRING 31-JAN-2027	204,918,033
СРН	ORDINARY FULLY PAID	204,918,033

## Proposed +issue date

22/5/2023

Refer to next page for full details of the announcement

### Part 1 - Entity and announcement details

\_\_\_\_

#### 1.1 Name of +Entity

CRESO PHARMA LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

## 1.2 Registered Number Type

**Registration Number** 

ACN

069406911

1.3 ASX issuer code

CPH

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

19/5/2023

1.6 The Proposed issue is:

A placement or other type of issue

# Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? 

✓ Yes

7A.1a Conditions

Approval/Condition

Date for determination

Is the date estimated or actual?

\*\* Approval received/condition met?

+Security holder approval

28/7/2023

No

#### Comments

Shareholder approval is required for 131,147,541 Options to unrelated Placement participants, and 73,770,492 Shares and 73,770,492 Options in respect of Adam Blumenthal's participation in the Placement.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities? ☑ Yes

Details of +securities proposed to be issued

ASX +security code and description

**CPH: ORDINARY FULLY PAID** 

Number of +securities proposed to be issued

204,918,033


Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash

What is the issue price per



consideration being paid?

+security?

AUD - Australian Dollar

AUD 0.01220

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Attaching +Security

Is the proposed attaching security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX)?

© Existing class

Attaching +Security - Existing class (additional +securities in a class that is already quoted or recorded by ASX)

Details of attaching +securities proposed to be issued

ASX +security code and description

CPHOD: OPTION EXPIRING 31-JAN-2027

Number of +securities proposed to be issued

204,918,033

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?  $\ensuremath{\mathfrak{C}}$  No

Please describe the consideration being provided for the +securities

Free attaching options under the Placement announced on 19 May 2023. Refer to ASX announcement for further details.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 7C - Timetable

7C.1 Proposed +issue date

22/5/2023

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? 

⊗ No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 

☑ No

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? 

✓ Yes

7D.1c (i) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?

131,147,541 Shares

7D.1c (ii) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security holders would have been eligible to participate

A placement offered the quickest, and most certain method of raising capital in the circumstances.

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? 

✓ Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? 

⊗ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

© No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue? 

✓ Yes

7E.1a Who is the lead manager/broker?

Everblu Capital Pty Ltd

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

6% cash fee together with 24,847,217 broker shares, which are subject to shareholder approval.

7E.2 Is the proposed issue to be underwritten?

**(**%

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Refer to ASX announcement dated 19 May 2023

Part 7F - Further Information

## 7F.01 The purpose(s) for which the entity is issuing the securities

To extinguish and repay existing debt, complete Halucenex's phase II clinical trial, as well as ongoing regulatory, M&A and product development initiatives.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?  $\ensuremath{\mathfrak{C}}$  No

7F.2 Any other information the entity wishes to provide about the proposed issue

Refer to the ASX announcement dated 19 May 2023 for further details.

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

☑ The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)